Loading...
Loading...
NeoStem, Inc. (NYSE Amex:NBS), a leader in the cell therapy industry, today
announced that it intends to offer and sell shares of its common stock and
warrants in an underwritten public offering. All of the shares and warrants in
the offering will be sold by NeoStem. The offering is subject to market
conditions, and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the offering. The
securities will be issued pursuant to a prospectus supplement filed as part of
an effective registration statement on Form S-3 previously filed with the
Securities and Exchange Commission.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in